Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 0.94 -0.02 (2.08%)
Day High: 0.99
Day Low:  0.92
Volume:    599,098
4:00 PM ET
Dec 8, 2016

Delayed ~20 min., by eSignal.